The aim of this study was to investigate the efficacy and safety of linagliptin ? low-dose (LD) metformin once daily versus high-dose (HD) metformin twice daily in treatment-naïve patients with type 2 diabetes.
Results: At Week 14, HbA1c changed from a mean baseline of 8.0% (64 mmol/mol) by -0.99% (-11 mmol/mol) for linagliptin ? LD metformin, and -0.98% (-11 mmol/mol) for HD metformin [treatment difference -0.01% (95% confidence interval -0.13, 0.12) (0 mmol/mol), P = 0.8924]. The proportion of patients who achieved HbA1c \7.0%
(53 mmol/mol) without occurrence of moderate or severe gastrointestinal (GI) events (including abdominal pain, nausea, vomiting, diarrhea, and decreased appetite) was the same in both groups (51.3% for both). Although the occurrence of moderate or severe GI events was Trial registration: ClinicalTrials.gov number, NCT01438814.
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INTRODUCTION
International guidelines for the treatment of type 2 diabetes mellitus (T2DM) collectively recommend metformin monotherapy, if not contraindicated, as first-line therapy [1] [2] [3] .
These guidelines advocate personalizing targets for glycemic control, generally defined by a glycated hemoglobin (HbA1c) level \7.0%
(53 mmol/mol) [1, 2] or B6.5% (48 mmol/mol) [3] . However, treatment with metformin is associated with gastrointestinal (GI) events, including nausea, vomiting, diarrhea, abdominal pain, and loss of appetite [1, 4] .
These symptoms limit its tolerability and may result in approximately 5% of patients discontinuing metformin treatment [5, 6] . GI disturbances may also reduce therapeutic adherence, potentially contributing to inadequate glycemic control. Therefore, metformin is initiated at a low dose (LD) and up-titrated to the maximum tolerated dose [1, 2] .
Some guidelines advocate initial treatment with combination therapy in patients with baseline HbA1c levels of C9% (75 mmol/mol) [1] or C7.5% (58 mmol/mol) [3] . This approach may also offer advantages when drug tolerability is a concern. For example, using lower doses of one or both drugs in the combination may minimize the adverse events (AEs) associated with the respective maximum dose monotherapies but without compromising the overall glucose-lowering efficacy [7] . Initial treatment with LD metformin plus another glucose-lowering drug could mitigate the tolerability issues associated with higher doses of metformin. LD metformin in combination with a dipeptidyl peptidase (DPP)-4 inhibitor is an attractive treatment option due to their complementary mechanisms of action which, together, target multiple pathophysiological defects of T2DM, with low additional risk for hypoglycemia and weight gain. Studies have shown that linagliptin plus metformin administered twice daily as add-on or initial combination therapy was effective and well tolerated for up to 2 years [8] [9] [10] . This combination did not increase the risk for hypoglycemia or weight gain, and GI tolerability was similar to that of metformin monotherapy. These results suggest this combination might be a valuable alternative treatment, especially for patients who do not tolerate higher or the maximum dose of metformin. Therefore, this study aimed to investigate the efficacy and safety of linagliptin 5 mg in combination with LD metformin once daily versus high-dose (HD) metformin twice daily in treatment-naïve patients with T2DM. 
METHODS

Study Design and Patients
Statistical Analysis
The primary endpoint was evaluated using an analysis of covariance (ANCOVA), with 'treatment' as a fixed classification effect and 'baseline HbA1c' as a linear covariate. This prespecified primary analysis was performed on the full analysis set (FAS 1000mg ), which comprised all randomized and treated patients with a baseline HbA1c measurement and C1 ontreatment HbA1c measurement, who tolerated a daily metformin dose of C1000 mg at the end of the titration phase. A last observation carried forward (LOCF) approach was used to replace missing data. Non-inferiority (with a margin of 0.35%) followed by superiority for the primary endpoint in a hierarchical sequence was used to test for the treatment effect of linagliptin ? LD metformin compared with HD metformin. The overall significance level was 5%. Sensitivity analyses were performed to assess the impact of missing data, important protocol violations, and premature discontinuation of trial medication on the primary endpoint. 
Sensitivity analyses utilized the FAS (LOCF),
RESULTS
Patient Disposition, Demographics, and Baseline Clinical Characteristics
The first patient was enrolled on November 24, 2011 and the last patient visit occurred on March 5, 2013. Patients (n = 689) were randomized to linagliptin ? LD metformin (n = 344) or HD metformin (n = 345); all patients received C1 dose of study drug (TS; Fig. 1 ). Overall, 661 (95.9%) patients completed the trial and 28 (4.1%) patients (n = 14 per group) prematurely discontinued. The most common reasons for discontinuation were 'lost to follow-up' (1.2%) and 'refusal to continue trial medication' (1.2%) in the linagliptin ? LD metformin group, and 'other' reasons (1.2%) in the HD metformin group. Of the patients in the FAS, 42 patients (12.4%) in the linagliptin ? LD metformin group were excluded from the FAS 1000mg as they did not tolerate a daily metformin dose of 1000 mg after 2 weeks; by contrast, no patients were excluded in the HD metformin group. The imbalance in the exclusion of patients from the FAS 1000mg was due to the design of this study, which specified different rules of discontinuation for the two groups. During the titration phase, patients who were unable to tolerate the starting dose of metformin (500 mg/day; both treatment groups) or tolerate metformin 1000 mg/day (HD metformin group only) were withdrawn from the trial. The FAS 1000mg consisted of 639 patients: linagliptin ? LD metformin, n = 298; HD metformin, n = 341.
Demographic and clinical characteristics were similar between treatment groups ( change: ?2.0 (2.1) mg/dL, 95% CI -2.1, 6.1, P = 0.3352] (Fig. 2b) . Rescue medication was required by one patient in the linagliptin ? LD metformin group and six patients in the HD metformin group.
Safety and Tolerability
Pre-specified GI AEs abdominal pain (linagliptin ? LD metformin 3.4%; HD metformin 6.2%).
In both groups, most patients had the first GI event during the first 2 weeks ( Figure S1 in the ESM). In the FAS 1000mg , the adjusted mean (SE) visual analog scores for pre-specified GI event severity assessed by patients were similar in both groups [linagliptin ? LD metformin 4.9 (0.2); HD metformin 4.4 (0.2)].
Change in Composite Endpoint
The proportion of patients who achieved HbA1c \7.0% (53 mmol/mol) without occurrence of pre-specified moderate or severe GI events was the same in both groups (linagliptin ? LD metformin 51.3%; HD metformin 51.3%; OR 0.960, 95% CI 0.67, 1.37, P = 0.8201). The proportion of patients who achieved C0.5% (6 mmol/mol) reduction in HbA1c without occurrence of pre-specified moderate or severe GI events after 14 weeks was similar (linagliptin ? LD metformin 65.1%; HD metformin 69.2%). Patients who achieved
HbA1c
\6.5% (48 mmol/mol) without occurrence of pre-specified moderate or severe GI events and who achieved C0.8% (9 mmol/mol) reduction in HbA1c without occurrence of pre-specified moderate or severe GI events after 14 weeks were similar between the groups (Table S2 in the ESM).
AEs and Hypoglycemia
The overall frequency of any AE and drugrelated AEs was comparable between groups, and AEs leading to discontinuation of trial medication were low ( 
DISCUSSION
Metformin is predominantly recommended as first-line therapy for the treatment of T2DM [1, 3] , unless it is contraindicated. In clinical practice, metformin can be up-titrated to a maximum daily dose of 2550 mg [11] , with maximum efficacy achieved at 2000 mg [5] . Metformin is well tolerated in the majority of patients; however, GI events are common and can occur in up to 30% of patients [5, [12] [13] [14] . These complications tend to occur soon after initiation of therapy [1, 15] and in particular when metformin is used at higher doses [5, 16] . To minimize GI events and improve tolerability, guidelines recommend that metformin is initiated at a low dose and is gradually up-titrated to the maximum tolerated dose [1] . Although in many patients GI events tend to resolve upon continued treatment, or with a reduction in metformin dose, the symptoms can be severe enough to limit or complicate optimal dose titration and therefore negatively impact treatment adherence and longterm glycemic control [17] .
This trial evaluated whether linagliptin 5 mg ? LD metformin once daily is a potential AEs leading to discontinuation of trial medication, n (%) 3 (0. TS-all patients who were treated with C1 dose of study medication AE adverse event, HD high dose, LD low dose, TS treated set alternative treatment to HD metformin twice daily with a focus on glycemic control and prespecified GI events in treatment-naïve patients with T2DM and insufficient glycemic control.
The results show that linagliptin ? LD metformin and HD metformin were equally effective and both substantially reduced HbA1c and FPG levels.
Furthermore, more than half of patients in both arms achieved a clinically relevant HbA1c target of\7.0% (53 mmol/mol). Since glycemic efficacy was similar in the combination group in the context of a substantially lower dose of metformin, linagliptin ? LD metformin may be an appropriate treatment alternative, especially in patients who cannot tolerate higher doses of metformin. In contrast to the design of the present study, the effects of combination therapy with linagliptin ? metformin have been investigated previously in the setting of equivalent doses of metformin monotherapy [8] and linagliptin monotherapy [18] . In the study by Haak et al. [8] , initial combination of linagliptin (2.5 mg twice daily) with LD (500 mg twice daily) or HD (1000 mg twice daily) metformin achieved superior glucose-lowering efficacy compared with the equivalent doses of metformin monotherapy. In the study by Ross et al. [18] , initial combination therapy with linagliptin (5 mg once daily) and metformin (up-titrated to 1000 mg twice daily) significantly improved glycemic control compared with the equivalent dose of linagliptin monotherapy. Studies of other DPP-4 inhibitors have also shown significant clinical benefit when administered as initial combination therapy with metformin and compared with the equivalent dose of metformin monotherapy [19] [20] [21] [22] [23] . Therefore, the combination of linagliptin and metformin may be an appropriate choice if glycemic control is not achieved with metformin monotherapy.
Although controlling hyperglycemia is the most important property of glucose-lowering therapies, consideration should be given to overall tolerability [1] . This is a particular concern when using combination therapy due to the potential increase in AEs. When administering multiple oral antihyperglycemic drugs, one approach to avoid excessive AEs is to use a LD combination strategy [7, 24, 25] This study was based on a relatively short duration of 14 weeks, which did not allow for assessments of long-term safety or durability of treatment efficacy. However, in a previous phase 3 study, the largest decrease in HbA1c occurred during the first 12 weeks of treatment for both the linagliptin ? metformin combination group and the metformin monotherapy group. Furthermore, in this study the maximum effect for the change in FPG was achieved in both groups by Week 2, which suggests that most of the expected reduction in HbA1c was achieved by Week 14. The combination of linagliptin plus metformin has also been shown to provide durable HbA1c reduction for up to 2 years [10] .
This study did not assess whether patients receiving HD metformin and who were experiencing GI AEs would benefit from switching to linagliptin ? LD metformin, which may have minimized the GI AEs without compromising the overall glucoselowering efficacy. In the present study, patients received immediate release metformin; however, extended release formulations of metformin are available which are associated with fewer GI AEs compared with immediate release metformin [12] . Other limitations include the lack of a forced titration scheme to up-titrate the dose of metformin and, because the study was conducted primarily (74%) in Asian and American Indian/Alaska native patients, the possible underrepresentation of white patients could affect the applicability of these results to the wider T2DM patient population.
CONCLUSION
This study shows that treatment with linagliptin ? LD metformin once daily provided similar glucose control to HD metformin twice daily in treatment-naïve patients with T2DM and insufficient glycemic control. The overall safety profile of linagliptin ? LD metformin combination therapy was comparable to HD metformin monotherapy, with a low incidence of hypoglycemia in both groups. Protocol-prespecified moderate and severe GI events were similar for the two treatments, although the linagliptin ? LD metformin group was associated with fewer mild GI events. Our findings suggest that linagliptin ? LD metformin once daily may be an alternative treatment option in patients who cannot tolerate metformin doses [1000 mg/day. 
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